RESUMO
Impaired wound healing complicates a wide range of diseases and represents a major cost to healthcare systems. Here we describe the use of discarded wound dressings as a novel, cost effective, accessible, and non-invasive method of isolating viable human cells present at the site of skin wounds. By analyzing 133 discarded wound dressings from 51 patients with the inherited skin-blistering disease epidermolysis bullosa (EB), we show that large numbers of cells, often in excess of 100 million per day, continually infiltrate wound dressings. We show, that the method is able to differentiate chronic from acute wounds, identifying significant increases in granulocytes in chronic wounds, and we show that patients with the junctional form of EB have significantly more cells infiltrating their wounds compared with patients with recessive dystrophic EB. Finally, we identify subsets of granulocytes and T lymphocytes present in all wounds paving the way for single cell profiling of innate and adaptive immune cells with relevance to wound pathologies. In summary, our study delineates findings in EB that have potential relevance for all chronic wounds, and presents a method of cellular isolation that has wide reaching clinical application.
Assuntos
Bandagens , Separação Celular , Epidermólise Bolhosa , Granulócitos , Linfócitos T , Cicatrização , Doença Aguda , Adulto , Doença Crônica , Epidermólise Bolhosa/metabolismo , Epidermólise Bolhosa/patologia , Epidermólise Bolhosa/terapia , Granulócitos/metabolismo , Granulócitos/patologia , Humanos , Masculino , Linfócitos T/metabolismo , Linfócitos T/patologiaRESUMO
INTRODUCCIÓN: La epidermólisis bullosa (EB) es un grupo heterogéneo de enfermedades mecanobulosas hereditarias caracterizadas por diversos grados de fragilidad cutánea y mucosa causada por mutaciones que afectan a las proteínas estructurales de la piel. Hay cuatro tipos principales de epidermólisis bullosa, los cuales se clasifican de acuerdo a nivel ultraestructural de tejido de piel: EB simple, EB de unión o juntural, EB distrófica y el síndrome de Kindler (13). La severidad está dada por el nivel de formación de ampollas y el tipo de mutación, lo que es muy variable entre los subtipos de EB. No existe un tratamiento específico y su evolución es crónica, llegando a mermar la calidad de vida de los pacientes y su familia, y su supervivencia. Los datos de la Asociación de Investigación de EB Distrófica de América (DEBRA) reportan una tasa de incidencia de 3,6 por millón por año para la EB de unión o juntural durante el período 2007 a 2011. Los datos de EB del Registro Australasian, proporcionaron una estimación de la prevalencia de 10 casos por millón de nacidos vivos, al igual que lo estimado en Chile, según DEBRA Chile (4), a su vez la incidencia reportada en Chile es de 19,6 casos nuevos por millón de nacidos vivos (5); la fundación DEBRA Chile, que agrupa a estos pacientes, informado para el informe de Redes, que actualmente existen 234 personas con EB, de los cuales el 60% presenta EB simple, mientras que el resto tiene tipos más severos y generalizados. Se considerarán para su evaluación aquellas solicitudes realizadas conforme al Reglamento que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con sistema de protección financiera, según lo establecido en los artículos 7° y 8° de la Ley N° 20.850. Estas solicitudes no son vinculantes para el Ministerio de Salud, debiendo, sin embargo, tomar especialmente en cuenta aquellas solicitudes y opiniones que hayan sido realizadas por sus comisiones técnicas asesoras y por las asociaciones de pacientes incluidas en el Registro de Asociaciones de Pacientes que crea la Ley 20.850. De igual forma, para ser incorporadas en el proceso de evaluación científica de la evidencia, cada intervención debe cumplir con los criterios establecidos en el Artículo 6o del Reglamento mencionado, según lo indicado en el Numeral 9 del presente informe. TECNOLOGÍAS SANITARIA DE INTERÉS: Los tratamientos evaluados se agruparon en: conjunto de medicamentos y en conjunto de insumos para curaciones, basado en la información entregada por la fundación DEBRA Chile. EFICACIA DE LOS TRATAMIENTOS: Según la norma técnica N°192 de la Evaluación científica de la evidencia elaborada por el Ministerio de Salud, que tiene como objetivo determinar el proceso de la misma, establece que en el caso de intervenciones cuya efectividad sea evidente sin necesidad de determinarla a través de estudios clínicos, se considerara a la vez significativa y con alta certeza en la evidencia. Por esta razón no se evalúa la eficacia del uso de dispositivos médicos para el tratamiento de epidermólisis bullosa. ALTERNATIVAS DISPONIBLES: Hasta el presente, no existe terapia específica para la EB. El tratamiento es de apoyo e incluye el cuidado de heridas, control de la infección, apoyo nutricional, prevención y tratamiento de las complicaciones. El manejo de los pacientes con EB implica un equipo multidisciplinario compuesto por dermatólogo, enfermera de EB, médico de atención primaria, terapeuta ocupacional, nutricionista, y un trabajador social, además de gastroenterólogos, oftalmólogos, nefrólogos, hematólogos, endocrinólogos, cardiólogos, manejo del dolor, cirugía plástica y odontología especializada. Este enfoque multidisciplinario se enfatiza por las recomendaciones de consenso multicéntrico para el cuidado de la piel en la EB hereditaria de 2014. CONCLUSIÓN: Para dar cumplimiento al artículo 28° del Reglamento que establece el proceso destinado a determinar los diagnósticos y tratamientos de alto costo con Sistema de Protección Financiera, según lo establecido en los artículos 7°y 8° de la ley N°20.850, aprobado por el decreto N°13 del Ministerio de Salud, se concluye que el presente informe de evaluación se considera favorable, de acuerdo a lo establecido en el Título III. de las Evaluaciones Favorables de la Norma Técnica N° 0192 de este mismo ministerio.
Assuntos
Humanos , Epidermólise Bolhosa/terapia , Controle de Infecções , Apoio Nutricional , Insumos Farmacêuticos , Técnicas de Fechamento de Ferimentos , Avaliação da Tecnologia Biomédica , Análise Custo-Benefício/economiaRESUMO
La epidermólisis bullosa comprende un grupo heterogéneo de enfermedades ampollosas de la piel y las mucosas, son de origen congénito y hereditario. Hacer el diagnóstico no es difícil si se tiene experiencia dermatológica, pero su clasificación es compleja y para ello se necesita considerar la clínica, la genética, la microscopia y la evaluación de laboratorio. El tratamiento de esta enfermedad es también dificultoso y son necesarias ciertas medidas, para proteger al paciente, evitar la aparición de lesiones y las complicaciones derivadas de ellas. Se describe el tratamiento de estas lesiones en un recién nacido, al que se administraron antibióticos profilácticos y se colocaron vendajes en las lesiones. Se describieron todos los cuidados y recomendaciones para evitar, especialmente los roces y las presiones en estas lesiones, así como las temperaturas altas. Para la confección del presente trabajo se consultaron 18 materiales entre revistas y libros de Pediatría. El caso reportado fue un recién nacido con epidermólisis bullosa atendido en el Hospital Universitario "Dr. Mario Muñoz Monroy" de Colón, Matanzas. Se demostró lo poco frecuente y raro de esta patología para los especialistas del tema (AU).
The epidermolysis bullosa includes a heterogeneous group of bullous skin and mucous diseases of congenital and hereditary origin. Diagnosing them is not difficult if the specialist has dermatologic experience, but their classification is complex and it is necessary to take into account the clinical, genetic and microscopic factors, and the laboratory assessment. The treatment of this disease is also difficult and it is necessary to take certain measures to protect the patient, avoid the onset of lesions and the complications derived from them. The treatment of these lesions in a newborn is described. Prophylactic antibiotics were administered and bandages were put on the lesions. All the cares and recommendations to avoid rubbings and pressures on these lesions, and also the high temperatures, are described. To develop the current term, 18 materials (journals and pediatric books) were consulted. The reported case was the case of a newborn with epidermolysis bullosa attended in the University Hospital "Dr. Mario Muñoz Monroy" of Colon, Matanzas. It was demonstrated the low frequency and rarity of this pathology for the specialists of the theme (AU).
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Dermatopatias Vesiculobolhosas/epidemiologia , Epidermólise Bolhosa/epidemiologia , Dermatopatias Vesiculobolhosas/congênito , Dermatopatias Vesiculobolhosas/diagnóstico , Epidermólise Bolhosa/complicações , Epidermólise Bolhosa/diagnóstico , Epidermólise Bolhosa/reabilitação , Epidermólise Bolhosa/terapia , Dermatologia/métodos , Doenças e Anormalidades Congênitas, Hereditárias e Neonatais/diagnóstico , Doenças e Anormalidades Congênitas, Hereditárias e Neonatais/genética , Doenças e Anormalidades Congênitas, Hereditárias e Neonatais/epidemiologiaRESUMO
Inherited epidermolysis bullosa (EB) is a heterogeneous group of genetic disorders that present with skin and, in some cases, mucosal fragility, predisposing patients to the development of blisters and/or erosions after minimal trauma or friction. Children with a recurrent history of these kinds of lesions or neonates that present them in the absence of another reasonable explanation should be investigated. Diagnosis must be based on clinical and histopathological findings. To date, management of inherited EB basically consists in avoiding traumas that trigger lesions, as well as preventing infection and facilitating healing of the wounds with the systematic use of bandages.
Assuntos
Epidermólise Bolhosa , Bandagens , Epidermólise Bolhosa/classificação , Epidermólise Bolhosa/genética , Epidermólise Bolhosa/patologia , Epidermólise Bolhosa/terapia , Humanos , Pele/patologia , CicatrizaçãoRESUMO
Inherited epidermolysis bullosa (EB) is a heterogeneous group of genetic disorders that present with skin and, in some cases, mucosal fragility, predisposing patients to the development of blisters and/or erosions after minimal trauma or friction. Children with a recurrent history of these kinds of lesions or neonates that present them in the absence of another reasonable explanation should be investigated. Diagnosis must be based on clinical and histopathological findings. To date, management of inherited EB basically consists in avoiding traumas that trigger lesions, as well as preventing infection and facilitating healing of the wounds with the systematic use of bandages.
A epidermólise bolhosa hereditária (EBH) compreende um grupo heterogêneo de desordens genéticas que têm em comum a fragilidade cutânea e, em alguns casos mucosa, predispondo ao desenvolvimento de bolhas e/ou erosões após fricção ou trauma mínimo. Crianças com história recorrente deste tipo de lesão ou neonatos que as apresentem na ausência de outra explicação plausível devem ser investigados. O diagnóstico deve se basear em achados clínicos e histopatológicos. Até o presente momento, o manejo da EBH consiste basicamente em evitar os traumas desencadeadores das lesões, bem como evitar a infecção e facilitar a cicatrização das feridas com o uso sistemático de curativos.
Assuntos
Humanos , Epidermólise Bolhosa , Bandagens , Epidermólise Bolhosa/classificação , Epidermólise Bolhosa/genética , Epidermólise Bolhosa/patologia , Epidermólise Bolhosa/terapia , Pele/patologia , CicatrizaçãoRESUMO
Epidermolysis bullosa (EB) has become recognized as a multisystem disorder that poses a number of pre-, intra-, and postoperative challenges. While anesthesiologists have long appreciated the potential difficult intubation in patients with EB, other systems can be affected by this disorder. Hematologic, cardiac, skeletal, gastrointestinal, nutritional, and metabolic deficiencies are foci of preoperative medical care, in addition to the airway concerns. Therefore, multidisciplinary planning for operative care is imperative. A multinational, interdisciplinary panel of experts assembled in Santiagio, Chile to review the best practices for perioperative care of patients with EB. This paper presents guidelines that represent a synthesis of evidence-based approaches and the expert consensus of this panel and are intended to aid physicians new to caring for patients with EB when operative management is indicated. With proper medical optimization and attention to detail in the operating room, patients with EB can have an uneventful perioperative course.
Assuntos
Epidermólise Bolhosa/complicações , Assistência Perioperatória , Anestesia por Inalação , Epidermólise Bolhosa/patologia , Epidermólise Bolhosa/terapia , Humanos , Salas Cirúrgicas , Dor Pós-Operatória/terapia , Cuidados Pós-Operatórios , Sistema Respiratório/patologiaRESUMO
Epidermolysis bullosa (EB) in Mexico continues to be a rare genodermatosis that is still unknown for most of the health care professionals in the country. The spirit of DebRA MEXICO was born in 1994 when the Mexican health care team started to see patients with the main purpose to provide medical care, genetic counseling, and advice to patients with EB and their families; to promote collaboration and exchange information among people with EB; to research and find new therapeutic approaches; and finally, to diffuse knowledge and raise awareness of the issues of EB in general public and health care professionals.
Assuntos
Epidermólise Bolhosa/terapia , Equipe de Assistência ao Paciente , Humanos , MéxicoRESUMO
UNLABELLED: Epidermolysis bullosa (EB) is a group of skin diseases with different clinical manifestations and varied inheritance patterns. Blisters may appear spontaneously or following minimal trauma to the skin or mucosa. AIM: this paper aims to describe the otorhinolaryngological manifestations and esophageal complications related to EB, and the experience in treating patients with esophageal stenosis secondary to this disease. MATERIALS AND METHOD: this descriptive study enrolled 60 patients with EB seen from June 1999 to December 2006 at the Head and Neck Surgery Service of X Hospital, a reference center for EB. RESULTS: the patients' mean age was 14.5 years. Twenty-eight (46.6%) were females and 32 (53.4%) were males. Eight (13.4%) were diagnosed with epidermolysis bullosa simplex, while 51 (85%) had epidermolysis bullosa dystrophica; one (1.6%) patient had one acquired EB. Lips, mouth, tongue and ears were the most frequently involved sites (32 patients - 53.3%). Dysphagia was found in 28 patients (46.6%). After esophageal dilatation the symptoms subsided. CONCLUSION: EB is a rare disease and patients must be sent for treatment at reference centers. Physicians treating patients for EB must be aware of the measures required to improve the quality of the treatment provided without putting the patients in harm's way.
Assuntos
Epidermólise Bolhosa/complicações , Doenças do Esôfago/etiologia , Otorrinolaringopatias/etiologia , Adolescente , Estudos de Casos e Controles , Criança , Pré-Escolar , Transtornos de Deglutição/etiologia , Epidermólise Bolhosa/terapia , Epidermólise Bolhosa Distrófica/complicações , Epidermólise Bolhosa Distrófica/terapia , Epidermólise Bolhosa Simples/complicações , Epidermólise Bolhosa Simples/terapia , Doenças do Esôfago/terapia , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Adulto JovemRESUMO
Epidermólise bolhosa (EB) é um conjunto de afecções bolhosas, de caráter hereditário, com diferentes quadros clínicos e diferentes modos de transmissão genética. Os indivíduos evoluem com bolhas na pele e mucosas, que surgem espontaneamente ou após mínimos traumatismos. OBJETIVO: Descrever as manifestações otorrinolaringológicas, as complicações esofágicas relacionadas à EB e a experiência na conduta de pacientes com estenose esofágica decorrente da EB. CASUÍSTICA E MÉTODO: Estudo descritivo de 60 pacientes com EB, atendidos de 1999 a 2006, no serviço de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço do Hospital X, centro de referência para EB. RESULTADOS: Dos 60 pacientes com idade média de 14,5 anos, 28 (46,6 por cento) eram mulheres e 32 (53,4 por cento) homens. Oito (13,4 por cento) tinham o diagnóstico de EB simples, 51 (85 por cento) EB distrófica e um (1,6 por cento) caso de EB adquirida. Lábios, boca, língua e pavilhão auricular foram os locais mais acometidos (32 pacientes - 53,3 por cento). Disfagia foi encontrada em 28 pacientes (46,6 por cento). Após dilatação do esôfago todos apresentaram remissão do sintoma. CONCLUSÃO: EB é uma doença rara e os pacientes devem ser encaminhados para tratamento em centros de referência. Portanto, é fundamental que os médicos envolvidos com os cuidados de pacientes com EB conheçam as condutas necessárias para melhorar a qualidade do tratamento sem prejuízos adicionais.
Epidermolysis bullosa (EB) is a group of skin diseases with different clinical manifestations and varied inheritance patterns. Blisters may appear spontaneously or following minimal trauma to the skin or mucosa. AIM: this paper aims to describe the otorhinolaryngological manifestations and esophageal complications related to EB, and the experience in treating patients with esophageal stenosis secondary to this disease. MATERIALS AND METHOD: this descriptive study enrolled 60 patients with EB seen from June 1999 to December 2006 at the Head and Neck Surgery Service of X Hospital, a reference center for EB. RESULTS: the patients' mean age was 14.5 years. Twenty-eight (46.6 percent) were females and 32 (53.4 percent) were males. Eight (13.4 percent) were diagnosed with epidermolysis bullosa simplex, while 51 (85 percent) had epidermolysis bullosa dystrophica; one (1.6 percent) patient had one acquired EB. Lips, mouth, tongue and ears were the most frequently involved sites (32 patients - 53.3 percent). Dysphagia was found in 28 patients (46.6 percent). After esophageal dilatation the symptoms subsided. CONCLUSION: EB is a rare disease and patients must be sent for treatment at reference centers. Physicians treating patients for EB must be aware of the measures required to improve the quality of the treatment provided without putting the patients in harm's way.